Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program
TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating.
Cadrenal Therapeutics Inc. (CVKD)
Market is closed
Sector: Healthcare
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.69 | 2,669 | $1,841.61 | 614,792 | 2023-10-05 | Filing | |
| $0.70 | 17,331 | $12,131.70 | 612,123 | 2023-10-04 | Filing | |
| $0.90 | 20,000 | $17,988.00 | 3,410,000 | 2023-09-05 | Filing | |
| $0.91 | 20,000 | $18,200.00 | 3,390,000 | 2023-09-05 | Filing | |
| $0.84 | 10,000 | $8,433.00 | 3,370,000 | 2023-09-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.03 | 7,400 | $22,422.00 | 98,589 | 2026-06-29 | Filing | |
| $3.05 | 9,029 | $27,538.45 | 105,989 | 2026-06-26 | Filing | |
| $3.00 | 2,127 | $6,381.00 | 115,018 | 2026-06-25 | Filing | |
| $3.20 | 2,277 | $7,286.40 | 117,145 | 2026-06-23 | Filing | |
| $3.55 | 9,167 | $32,542.85 | 119,422 | 2026-06-22 | Filing |
News See All
8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
Hedge Fund Resource Center